Progressive pulmonary fibrosis market expected to nearly double to $2.7b by 2035

Cheaper generics will compete with branded and pipeline drugs.

The progressive pulmonary fibrosis (PPF) market across the seven major markets is projected to grow from $1.3b in 2025 to $2.7b in 2035, according to GlobalData.

Growth is expected to be driven by new therapies entering the market, including the launch of Jascayd (nerandomilast) in Europe and Japan, as well as several late-stage pipeline drugs expected before 2035.

“This pipeline is expected to offer safer treatment options for patients, including inhaled add-on therapies to assist the current standard of care,” said Connor Daniels, healthcare analyst at GlobalData. “This could reduce the reliance on a limited number of antifibrotic therapies with considerable tolerability issues, specifically gastrointestinal disturbances.”

He also pointed to potential improvements in slowing forced vital capacity (FVC) decline compared with existing therapies.

In 2025, the market was largely dominated by Ofev (nintedanib), the current standard antifibrotic therapy. The entry of Jascayd into the U.S. in late 2025 marked the first major new treatment in years.

Further approvals are expected over the forecast period, including admilparant from Bristol Myers Squibb anticipated in 2027, and Tyvaso (treprostinil) from United Therapeutics expected in 2029. Additional late-stage candidates include treprostinil palmitil from Insmed and AP-01 from Avalyn Pharma.

Despite these developments, the report noted that current treatments only slow disease progression and do not stop or reverse it. Unmet need remains high due to limited efficacy and tolerability issues with existing drugs.

The pipeline is expected to introduce inhaled and oral therapies with new mechanisms of action, potentially improving tolerability and outcomes. However, challenges remain, including slow clinician adoption, high treatment costs, and upcoming generic competition.

“The PPF market will still be constrained by several barriers, most notably the entry of generics for nintedanib and nerandomilast, which offer cheaper alternatives to their branded originators as well as to pipeline drugs,” said Daniels.

He added that adoption of new therapies may be slow due to limited clinician experience with new mechanisms, and high costs that could restrict patient access, particularly when used alongside existing standard treatments.